This firm-fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The $22,179 contract is for gene synthesis and cloning services to support ongoing research on respiratory syncytial virus (RSV)-associated illness and pneumonia. This work involves analyzing precious clinical samples already in progress. The contract does not have a set-aside designation. Genscript has a history of providing specialized biological materials and services, such as gene synthesis, protein production, and diagnostic test kits, to support federal agencies' public health and biomedical research initiatives, including efforts related to emerging infectious diseases like COVID-19 and HIV.
Generated 2/20/25, 9:13 AM